Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.580
+0.160 (6.61%)
At close: Aug 29, 2025, 4:00 PM
2.630
+0.050 (1.93%)
After-hours: Aug 29, 2025, 7:58 PM EDT
Fortress Biotech Stock Forecast
Stock Price Forecast
The 2 analysts that cover Fortress Biotech stock have a consensus rating of "Strong Buy" and an average price target of $16.5, which forecasts a 539.53% increase in the stock price over the next year. The lowest target is $16 and the highest is $17.
Price Target: $16.5 (+539.53%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Fortress Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $26 → $17 | Strong Buy | Maintains | $26 → $17 | +558.91% | Aug 21, 2025 |
| Roth MKM | Roth MKM | Strong Buy Reiterates $15 → $16 | Strong Buy | Reiterates | $15 → $16 | +520.16% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $24 → $26 | Strong Buy | Maintains | $24 → $26 | +907.75% | Nov 18, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +830.23% | Jul 19, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
Financial Forecast
Revenue This Year
87.43M
from 57.68M
Increased by 51.59%
Revenue Next Year
126.54M
from 87.43M
Increased by 44.74%
EPS This Year
-1.43
from -2.69
EPS Next Year
-0.84
from -1.43
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 108.2M | 154.1M | |
| Avg | 87.4M | 126.5M | |
| Low | 67.0M | 99.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 87.7% | 76.3% | |
| Avg | 51.6% | 44.7% | |
| Low | 16.1% | 13.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.26 | -0.47 | |
| Avg | -1.43 | -0.84 | |
| Low | -1.57 | -1.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.